Melbourne Clinical Trials
Star Study
This study is looking at a new treatment for vision loss due to a condition known as Stargardt’s disease. Stargardt’s disease is a genetic condition which leads to vision loss due to damage to several parts of the eye.
2 x 2 nights nights
6 + 6 eye appointments visits
The medication is administered via oral capsules and has already been tested at Nucleus Network in a group of 75 participants where no serious side effects were observed. This study is comparing the medication given in that study with a different formulation that is processed to make a more consistent drug particle size and shape.
The trial has been approved by an independent ethics committee and you will be reimbursed for your time.
Eligibility
Biological Sex Healthy males or females
Age 18-55 years old
BMI 18-32 kg/m²
Medications Not taking medication (contraceptives are permitted)
Medical History Nothing significant